Sun Nelson 4

What Happened

• Sun Nelson, Chief Financial Officer of Aardvark Therapeutics (AARD), was granted 70,549 derivative securities on February 9, 2026. The Form 4 reports a $0.00 price for the award, indicating no immediate cash outlay. This is an equity compensation grant (derivative award), not a market purchase or sale.

Key Details

• Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (timely filing).
• Grant amount: 70,549 derivative securities; reported price $0.00 and reported value $0.
• Shares owned after the transaction: not specified in the provided summary of the filing.
• Footnote (vesting): 1/4 of the award vests on Feb 9, 2027, then 1/48 of the award vests monthly thereafter, subject to continuous service through each vesting date.
• Transaction type: Code A (award/acquisition of a derivative security). No sale or open-market purchase was reported.

Context

• This entry is a standard equity-compensation grant to an executive. Derivative awards typically vest over time and may convert to common shares or become exercisable according to the vesting schedule; they do not represent an immediate sale or buy signal. The timely filing indicates routine reporting compliance.